medicaid glp 1 weight loss GLP-1s prescriptions for are skyrocketing in North Carolina More states consider dropping GLP-1
Description
Victorino DB, Nejm M, Guimares-Marques M, Scorza FA, Scorza CA (2021) Repurposing GLP-1 receptor agonists for Parkinsons disease: current evidence and future opportunities

Only around 9% of employers have no cost-control measures in place

Competitive binding of GLP-1(9-36) in the presence and absence of 10 M positive allosteric modulator (PAM) LSN3160440 was measured using 4 nM labeled exendin-4

10.1161/JAHA.123.033654 150 WalshS.MerrickR.MilneR.BrayneC
